Raymond James Financial
FTH

Raymond James Financial’s Faeth Therapeutics FTH Stock Holding History

Raymond James Financial’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-700
Closed -$6.01K – 6503
2025
Q2 		$6.01K Hold
700
– – ﹤0.01% 6106
2025
Q1 		$5.52K Hold
700
– – ﹤0.01% 4796
2024
Q4 		$6.86K Buy
+700
New +$7.02K ﹤0.01% 4783

Other funds holding FTH

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Raymond James Financial's FTH Position: Q3 2025 in Review

Raymond James Financial sold out of Faeth Therapeutics (FTH) in Q3 2025, closing a stake of 700 shares — an estimated $6.01K sold.

Raymond James Financial first reported a position in FTH in Q4 2024 and held it in 3 quarters. The position peaked at $6.86K in Q4 2024. 9 funds tracked by Wall St. Rank hold FTH as of Q3 2025.

  • Raymond James Financial reported no remaining Faeth Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 700 Faeth Therapeutics shares in Q3 2025, an estimated $6.01K.
  • Raymond James Financial first reported a position in Faeth Therapeutics in Q4 2024 and held it in 3 quarters.
  • Raymond James Financial's Faeth Therapeutics position peaked at $6.86K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.